DOPF

DOPF
Clinical data
Other namesDOPF; 2,5-Dimethoxy-4-(3-fluoropropyl)amphetamine; 4-(3-Fluoropropyl)-2,5-dimethoxyamphetamine
Routes of
administration		Unknown[1]
Pharmacokinetic data
Duration of actionUnknown[1]
Identifiers
  • 2-[4-(3-fluoropropyl)-2,5-dimethoxyphenyl]ethanamine
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H22FNO2
Molar mass255.333 g·mol−1
3D model (JSmol)
  • COc1cc(CCCF)c(cc1CC(C)N)OC
  • InChI=1S/C14H22FNO2/c1-10(16)7-12-9-13(17-2)11(5-4-6-15)8-14(12)18-3/h8-10H,4-7,16H2,1-3H3
  • Key:UIHSFMYQJAKMHD-UHFFFAOYSA-N

DOPF, also known as 2,5-dimethoxy-4-(3-fluoropropyl)amphetamine, is a designer drug from the amphetamine and DOx families.[1] It was first synthesised by Alexander Shulgin and David Nichols in 1989 but was never published at the time, and was finally disclosed in Daniel Trachsel's review of the field in 2013.[1] It has a binding affinity (Ki) of 9 nM at the serotonin receptor 5-HT2A but is not known to have been tested in humans.[1] DOPF is a controlled substance in Canada under phenethylamine blanket-ban language.[2]

See also

References

  1. ^ a b c d e Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine Von der Struktur zur Funktion [Phenethylamine From structure to function] (in German). Nachtschatten Verlag AG. p. 778-780. ISBN 978-3-03788-700-4.
  2. ^ "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.